BR9809398A - Quinazolinonas que inibem a farnesil transferase - Google Patents
Quinazolinonas que inibem a farnesil transferaseInfo
- Publication number
- BR9809398A BR9809398A BR9809398-3A BR9809398A BR9809398A BR 9809398 A BR9809398 A BR 9809398A BR 9809398 A BR9809398 A BR 9809398A BR 9809398 A BR9809398 A BR 9809398A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- alkyloxy
- hydrogen
- halo
- optionally substituted
- Prior art date
Links
- 102000007317 Farnesyltranstransferase Human genes 0.000 title abstract 2
- 108010007508 Farnesyltranstransferase Proteins 0.000 title abstract 2
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004951 trihalomethoxy group Chemical group 0.000 abstract 2
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C07D239/82—Oxygen atoms with an aryl radical attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Patente de Invenção:<B>"QUINAZOLINONAS QUE INIBEM A FARNESIL TRANSFERASE"<D>. Esta invenção diz respeito aos compostos de fórmula (I), aos sais de adição de ácido farmaceuticamente aceitáveis e as suas formas estereoquimicamente isoméricas, onde a linha pontilhada representa uma ligação opcional; X é oxigênio ou enxofre; R^ 1^ e R^ 2^, cada um independentemente, são hidrogênio, hidróxi, halo, ciano, C~ 1-6~alquila, trihalometila, trihalometóxi, C~ 2-6~alquenila, C~ 1-6~alquilóxi, hidróxiC~ 1-6~alquilóxi, C~ 1-6~alquilóxiC~ 1-6~alquilóxi, C~ 1-6~alquilóxicarbonila, aminoC~ 1-6~alquilóxi, mono- ou di(C~ 1-6~alquil)aminoC~ 1-6~alquilóxi, Ar^ 1^, Ar^ 1^C~ 1-6~alquila, Ar^ 1^óxi, Ar^ 1^C~ 1-6~alquilóxi; ou quando em posições adjacentes, R^ 1^ e R^ 2^representados juntos podem formar um radical bivalente; R^ 3^ e R^ 4^, cada um independentemente, são hidrogênio, halo, ciano, C~ 1-6~alquila; C~ 1-6~alquilóxi, Ar^ 1^oxi, C~ 1-6~alquiltio, di(C~ 1-6~alquil)amino, trihalometila, trihalometóxi; R^ 5^ é hidrogênio, halo, ciano, C~ 1-6~alquila opcionalmente substituída, C~ 1-6~alquilóxicarbonila ou Ar^ 1^; ou um radical de fórmula -OR^ 10^, -SR^ 10^, -NR^ 11^R^ 12^; R^ 6^ é uma porção de imidazolila opcionalmente substituída; R^ 7^ é hidrogênio ou C~ 1-6~alquila, desde que a linha pontilhada não represente uma ligação; R^ 8^ é hidrogênio, C~ 1-6~alquila ou Ar^ 2^CH~ 2~ ou Het^ 1^CH~ 2~; R^ 9^ é hidrogênio, C~ 1-6~alquila, C~ 1-6aquilóxi ou halo, ou R^ 8^ e R^ 9^ representados juntos podem formar um radical bivalene; Ar^ 1^ e Ar^ 2^ são fenila opcionalmente substituída e Het^ 1^ é piridinila opcionalmente substituída; tendo atividade de inibição da farnesiltransferase; a sua preparação, às composições contendo os mesmos e ao seu uso como um medicamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97201259 | 1997-04-25 | ||
| PCT/EP1998/002357 WO1998049157A1 (en) | 1997-04-25 | 1998-04-17 | Farnesyltransferase inhibiting quinazolinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9809398A true BR9809398A (pt) | 2000-06-13 |
Family
ID=8228267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9809398-3A BR9809398A (pt) | 1997-04-25 | 1998-04-17 | Quinazolinonas que inibem a farnesil transferase |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6177432B1 (pt) |
| EP (1) | EP0977750B1 (pt) |
| JP (1) | JP4308919B2 (pt) |
| KR (1) | KR100520401B1 (pt) |
| CN (1) | CN1094937C (pt) |
| AT (1) | ATE366250T1 (pt) |
| AU (1) | AU738628B2 (pt) |
| BR (1) | BR9809398A (pt) |
| CA (1) | CA2288140C (pt) |
| CZ (1) | CZ296959B6 (pt) |
| DE (1) | DE69838025T2 (pt) |
| ES (1) | ES2289783T3 (pt) |
| HU (1) | HUP0001122A3 (pt) |
| IL (1) | IL130363A (pt) |
| NO (1) | NO317576B1 (pt) |
| NZ (1) | NZ336233A (pt) |
| PL (1) | PL190944B1 (pt) |
| RU (1) | RU2205831C2 (pt) |
| SK (1) | SK146199A3 (pt) |
| TR (1) | TR199902606T2 (pt) |
| WO (1) | WO1998049157A1 (pt) |
| ZA (1) | ZA983504B (pt) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2205831C2 (ru) * | 1997-04-25 | 2003-06-10 | Янссен Фармацевтика Н.В. | Хиназолиноны, ингибирующие фарнезилтрансферазу |
| HRP20000904A2 (en) | 1998-07-06 | 2001-12-31 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibitors for treating arthropathies |
| WO2000034437A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2000034239A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| ID29241A (id) * | 1998-12-23 | 2001-08-16 | Janssen Pharmaceutica Nv | Turunan-turunan kinolin teranelasi-1,2 |
| KR20010077400A (ko) * | 2000-02-02 | 2001-08-17 | 성재갑 | 에프타아제 저해제인 엘비42908과 타(他) 항암제와의조합에 의한 항암치료제 |
| JP5491681B2 (ja) * | 2000-02-04 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤 |
| US6838467B2 (en) | 2000-02-24 | 2005-01-04 | Janssen Pharmaceutica N. V. | Dosing regimen |
| JP2003525239A (ja) * | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 |
| US20030078281A1 (en) * | 2000-02-29 | 2003-04-24 | Rybak Mary Ellen Margaret | Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents |
| WO2001064196A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| WO2001064194A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| JP2003525252A (ja) * | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 |
| CA2397448A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| EP1261343A2 (en) * | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| US20030027808A1 (en) * | 2000-02-29 | 2003-02-06 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| AU2001244167A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| AU2001252147A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations |
| EP1267871A2 (en) * | 2000-02-29 | 2003-01-02 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| JO2361B1 (en) * | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
| US7067531B2 (en) | 2000-09-25 | 2006-06-27 | Angibaud Patrick Rene | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
| WO2002024682A1 (en) * | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| WO2002024686A2 (en) * | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
| US7173040B2 (en) | 2000-09-25 | 2007-02-06 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives |
| JP4348080B2 (ja) * | 2000-11-21 | 2009-10-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害するベンゾ複素環誘導体 |
| DK1339407T3 (da) * | 2000-11-28 | 2006-08-14 | Janssen Pharmaceutica Nv | Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom |
| ES2260316T3 (es) | 2000-12-27 | 2006-11-01 | Janssen Pharmaceutica N.V. | Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa. |
| JP4969016B2 (ja) * | 2001-02-15 | 2012-07-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物 |
| BRPI0208075B8 (pt) * | 2001-03-12 | 2021-05-25 | Janssen Pharmaceutica Nv | processo para a preparação de compostos de imidazol |
| US20020177575A1 (en) * | 2001-05-04 | 2002-11-28 | Ward Wakeland | Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies |
| ATE425978T1 (de) * | 2001-12-19 | 2009-04-15 | Janssen Pharmaceutica Nv | Durch c-verbundene imidazole substituierte 1,8- annellierten chinolon-derivate als farnesyl transferase inhibitoren |
| FR2837201A1 (fr) * | 2002-03-18 | 2003-09-19 | Servier Lab | Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP4450628B2 (ja) | 2002-03-22 | 2010-04-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼインヒビターとして使用するためのベンジルイミダゾリル置換２−キノリンおよびキナゾリン誘導体 |
| ATE336496T1 (de) | 2002-04-15 | 2006-09-15 | Janssen Pharmaceutica Nv | Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen |
| US20030125268A1 (en) * | 2002-08-28 | 2003-07-03 | Rybak Mary Ellen Margaret | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| US20050272068A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | UCH-L1 expression and cancer therapy |
| US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| JP2007529555A (ja) * | 2004-03-18 | 2007-10-25 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | シヌクレイノパチーを治療する方法 |
| CA2559285A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| EP1655289A1 (en) * | 2004-11-04 | 2006-05-10 | Embl | Quinazoline derivatives, process for their preparation, their use as antimitotics and pharmaceutical compositions comprising said derivatives |
| HRP20130399T1 (hr) | 2004-11-05 | 2013-06-30 | Janssen Pharmaceutica Nv | Terapeutska upotreba inhibitora farenziltransferaze i postupci praä†enja njihove efikasnosti |
| US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
| EP1871347B1 (en) | 2005-04-19 | 2016-08-03 | Novartis AG | Pharmaceutical composition |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| CA2634598A1 (en) | 2005-12-23 | 2007-07-05 | Link Medicine Corporation | Treatment of synucleinopathies |
| WO2007124319A1 (en) | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
| PL2021335T3 (pl) | 2006-04-20 | 2011-10-31 | Janssen Pharmaceutica Nv | Związki heterocykliczne jako inhibitory kinazy C-FMS |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| CN101600698B (zh) | 2006-09-11 | 2012-01-11 | 欧加农股份有限公司;药典有限责任公司 | 喹唑啉酮和异喹啉酮乙酰胺衍生物 |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
| WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| NZ593090A (en) * | 2008-11-13 | 2013-06-28 | Link Medicine Corp | Azaquinolinone derivatives and uses thereof |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| US8431576B2 (en) | 2009-06-25 | 2013-04-30 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| ES2705719T3 (es) | 2010-07-28 | 2019-03-26 | Janssen Diagnostics Llc | Métodos de determinación de la respuesta de la leucemia mieloide aguda al tratamiento con inhibidores de la farnesiltransferasa |
| ES2658773T3 (es) | 2012-08-07 | 2018-03-12 | Janssen Pharmaceutica N.V. | Procedimiento de sulfonilación usando fluoruro de nonafluorobutanosulfonilo |
| CN104870454B (zh) | 2012-08-07 | 2020-03-03 | 詹森药业有限公司 | 用于制备杂环酯衍生物的方法 |
| CN103275085B (zh) * | 2013-05-30 | 2015-04-08 | 温州大学 | 一种喹唑啉并喹唑啉酮化合物及其合成方法和用途 |
| SMT202100712T1 (it) | 2015-08-17 | 2022-01-10 | Kura Oncology Inc | Metodi di trattamento di pazienti di cancro con inibitori di farnesil trasferasi |
| TW201818965A (zh) | 2016-11-03 | 2018-06-01 | 美商庫拉腫瘤技術股份有限公司 | 以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法 |
| WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| US20220143006A1 (en) | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2002864C (en) * | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| US5430148A (en) * | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
| WO1994007498A1 (fr) * | 1992-10-07 | 1994-04-14 | Sumitomo Pharmaceuticals Company, Limited | Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale |
| TW321649B (pt) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| RU2205831C2 (ru) * | 1997-04-25 | 2003-06-10 | Янссен Фармацевтика Н.В. | Хиназолиноны, ингибирующие фарнезилтрансферазу |
-
1998
- 1998-04-17 RU RU99124815/04A patent/RU2205831C2/ru active
- 1998-04-17 HU HU0001122A patent/HUP0001122A3/hu unknown
- 1998-04-17 ES ES98924161T patent/ES2289783T3/es not_active Expired - Lifetime
- 1998-04-17 AU AU76460/98A patent/AU738628B2/en not_active Expired
- 1998-04-17 IL IL13036398A patent/IL130363A/en not_active IP Right Cessation
- 1998-04-17 CZ CZ0371799A patent/CZ296959B6/cs not_active IP Right Cessation
- 1998-04-17 CA CA002288140A patent/CA2288140C/en not_active Expired - Lifetime
- 1998-04-17 KR KR10-1999-7005507A patent/KR100520401B1/ko not_active Expired - Fee Related
- 1998-04-17 BR BR9809398-3A patent/BR9809398A/pt not_active Application Discontinuation
- 1998-04-17 DE DE69838025T patent/DE69838025T2/de not_active Expired - Lifetime
- 1998-04-17 US US09/403,705 patent/US6177432B1/en not_active Expired - Lifetime
- 1998-04-17 EP EP98924161A patent/EP0977750B1/en not_active Expired - Lifetime
- 1998-04-17 TR TR1999/02606T patent/TR199902606T2/xx unknown
- 1998-04-17 JP JP54656198A patent/JP4308919B2/ja not_active Expired - Lifetime
- 1998-04-17 PL PL336468A patent/PL190944B1/pl unknown
- 1998-04-17 AT AT98924161T patent/ATE366250T1/de not_active IP Right Cessation
- 1998-04-17 WO PCT/EP1998/002357 patent/WO1998049157A1/en not_active Ceased
- 1998-04-17 NZ NZ336233A patent/NZ336233A/xx unknown
- 1998-04-17 SK SK1461-99A patent/SK146199A3/sk unknown
- 1998-04-17 CN CN98804366A patent/CN1094937C/zh not_active Expired - Lifetime
- 1998-04-24 ZA ZA9803504A patent/ZA983504B/xx unknown
-
1999
- 1999-10-22 NO NO19995169A patent/NO317576B1/no unknown
-
2000
- 2000-10-13 US US09/687,153 patent/US6358961B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9809398A (pt) | Quinazolinonas que inibem a farnesil transferase | |
| BR9808843A (pt) | Derivados de quinolinona 1,8-anelados inibidores da farnesil transferase substituìdos com imidazóis ligados em n ou em c | |
| EA199800395A1 (ru) | Производные 2-хинолона, ингибирующие фарнезилтрансферазу | |
| BR9809468A (pt) | Formulações farmacêuticas contendo voriconazol | |
| DK1392713T3 (da) | Lever-X-receptoragonister | |
| MY114444A (en) | Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl -2-quinolone derivatives | |
| BR0307624A (pt) | Inibidores de histona desacetilase | |
| BR9708099A (pt) | Formulações de propofol em microgotìculas. | |
| BR9916211A (pt) | Derivados de 3,4-diamino-3-ciclobuteno-1,2-diona que inibem adesão de leucócito mediada por vla-4 | |
| BR9916198A (pt) | Formulações pesticidas contendo semi-éster de sulfato de triestirilfenol alcoxilado neutralizado com tensoativos de amina alcoxilados | |
| EP1118336A3 (en) | Somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells | |
| BR9812922A (pt) | Isoquinolinas como inibidores de uroquinase | |
| BR9811769A (pt) | Tetraidro gama-carbolinas | |
| BR9814376A (pt) | Composto ou um pró-medicamento correspondente, ou um sal farmaceuticamente aceitável ou solvato de um tal composto ou um pró-medicamento deste, uso destes, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano sofrendo de, ou sujeito a, condições que podem ser melhoradas pela admnistração de um inibidor da adesão celular mediada por &4ß1, e, resina | |
| ES2170177T3 (es) | Benzotienilpiperazinas sustituidas, su uso como medicamentos y procedimientos para su preparacion. | |
| ATE325116T1 (de) | Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate | |
| BR9811679A (pt) | Antifúngicos de 1,3-dioxolanos 2,4,4-trissubstituìdos. | |
| BR0013840A (pt) | Análogos monoméricos de insulina humana | |
| BR9811499A (pt) | "derivados da 6-azauracila como inibidores da il-5" | |
| BR9902347A (pt) | Azabiciclos como inibidores de rotomase | |
| ATE434615T1 (de) | Farnesyltransferase hemmende benzoheterocyclische derivate | |
| DE69511247D1 (de) | Therapeutische benzonitrile | |
| BR0212717A (pt) | Composição herbicida | |
| PT1353929E (pt) | Derivados de estreptograminas sua preparacao e composicoes que os contem | |
| MX9710034A (es) | Compuestos de bencimidazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |